PCA
RPRX icon

Pallas Capital Advisors’s Royalty Pharma RPRX Stock Holding History

Pallas Capital Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.94M Sell
102,969
-8,157
-7% -$357K 0.19% 106
2025
Q4 		$4.29M Buy
111,126
+6,544
+6% +$250K 0.14% 120
2025
Q3 		$3.69M Buy
104,582
+1,341
+1% +$48.5K 0.14% 124
2025
Q2 		$3.72M Buy
103,241
+2,794
+3% +$92.6K 0.14% 120
2025
Q1 		$3.13M Buy
100,447
+8,113
+9% +$257K 0.13% 137
2024
Q4 		$2.36M Buy
+92,334
New +$2.45M 0.1% 147
2023
Q2 		– Sell
-20,982
Closed -$752K – 295
2023
Q1 		$752K Sell
20,982
-731
-3% -$27.1K 0.07% 163
2022
Q4 		$832K Buy
+21,713
New +$906K 0.08% 164

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $95.1B AUM 30.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return